COVID-19 MONOCLONAL ANTIBODY TREATMENT

COVID-19 Monoclonal Antibody Treatment

There are TWO different ways to qualify for treatment:

1.  Treatment of Active Infection

  • be 12 years or older;
  • weigh at least 88 lbs;
  • be at high risk for progressing to severe COVID-19 (*see high risk list below);
  • have tested positive for COVID-19;
  • be within 10 days of symptom onset (ideally as soon as possible after diagnosis, even if symptoms are not too bad); AND
  • not be receiving oxygen therapy.

2.  Post-Exposure Prophylaxis (Prevention)

  • be 12 years or older;
  • weigh at least 88 lbs;
  • be at high risk for COVID-19 (*see high risk list below);
  • not fully vaccinated OR not expected to be fully immune;
  • known exposure or have high risk to being exposed
Prognosis icon ge62d5cadb 1920
*High risk includes any of the following:
  • 65 years or older;
  • Chronic kidney disease;
  • Heart or lung disease;
  • BMI of 25 or greater;
  • Pregnancy;
  • Diabetes;
  • Sickle cell disease;
  • Neurodevelopmental disorders (for example, cerebral palsy);
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID 19); OR
  • Other medical conditions or factors (for example, race or ethnicity) that may also place individual patients at high risk for progression to severe COVID-19.

REGEN-COV is not approved for use in patients who are hospitalized due to COVID-19 or who require oxygen therapy. Benefits of treatment have not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies may be associated with worse clinical outcomes when given to patients with COVID-19 requiring oxygen ventilation.

We offer mAb treatments by appointment only.  Submit this form by clicking on the red button below to inform us how you qualify.  We will contact you to schedule your appointment.
Monoclonal Antibody Treatment Form

What are Monoclonal Antibodies (mAb)?

mAb are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. They are used to treat an existing SARS-CoV-2 infection and may help prevent progression of the disease that would otherwise require hospitalization.

mAb treatment for COVID-19 is an investigational medicine and not a substitute for getting vaccinated. The vaccine trains the body to recognize the virus to be able to fight a future infection, while mAb is used to combat a current infection. To note, protection from a COVID-19 vaccine lasts longer than treatment from mAb therapy. Where possible, it is preferable to get vaccinated rather than to contract COVID-19 and need mAb therapy.

The monoclonal antibody treatment that we provide is called REGEN-COV, which is made up of the drugs casirivimab and imdevimab. They are administered together via four subcutaneous injections. Please refer to the FDA's EUA for patients: